RE:RE:RE:RE:RE:RE:RE:The Comapny Performed, Management disappointed. Few in pipeline are likely blockbuster drugs and will be added to portfolio over time and without fanfare as stated by management. Few if any are game changers in themselves, but in total will contribute to growth and strategic planning. Do not expect PR releases but watch the top line in ERs. Ticker is right on here. Select continues to think he is the market maker when he is just riding the coattails of the real MMs who have been very active in cxr.